AIC
MTNB icon

Ameritas Investment Company’s Matinas BioPharma MTNB Stock Holding History

Ameritas Investment Company’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-112
Closed -$3K – 1124
2020
Q1 		$3K Buy
+112
New +$6.76K ﹤0.01% 1506
2019
Q2 		– Sell
-112
Closed -$6K – 610
2019
Q1 		$6K Buy
+112
New +$6.03K ﹤0.01% 726

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ameritas Investment Company's MTNB Position: Q2 2020 in Review

Ameritas Investment Company sold out of Matinas BioPharma (MTNB) in Q2 2020, closing a stake of 112 shares — an estimated $3K sold.

Ameritas Investment Company first reported a position in MTNB in Q1 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 65 funds tracked by Wall St. Rank hold MTNB as of Q2 2020.

  • Ameritas Investment Company reported no remaining Matinas BioPharma position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 112 Matinas BioPharma shares in Q2 2020, an estimated $3K.
  • Ameritas Investment Company first reported a position in Matinas BioPharma in Q1 2019 and held it in 2 quarters.
  • Ameritas Investment Company's Matinas BioPharma position peaked at $6K in Q1 2019.
  • 65 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.